Rosetta Genomics Announces it has Presented Data on Advancements Made in the Company's Lead Assay Development Program for Cancer of Unknown Primary (CUP)

REHOVOT, Israel and NEW BRUNSWICK, New Jersey, April 20

Apr 20, 2007, 01:00 ET from Rosetta Genomics Ltd

/PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDAQ:   ROSG), announced
 today that it has presented updated results on its lead diagnostic
 development program for cancer of unknown primary (CUP), at the Annual
 Meeting of the American Association for Cancer Research (AACR), in Los
 Angeles, California.
     The poster, titled "MicroRNA Signature for Identification of Tumor
 Origin" presented the expansion of the company's CUP assay to include 15
 major cancer types, identifiable through a unique signature of 19 microRNAs
 with 85% accuracy. In addition, data was presented regarding Rosetta
 Genomics' proprietary methods for extraction and profiling of microRNAs.
     The poster is available for viewing on the company's web site through
 the following link:
     About microRNAs
     MicroRNAs (miRNAs) are recently discovered, naturally occurring small
 RNAs that act as protein regulators and have the potential to form the
 basis for a new class of diagnostics and therapeutics. Since many diseases
 are caused by the abnormal activity of proteins, the ability to selectively
 regulate protein activity through microRNAs could provide the means to
 treat a wide range of human diseases. In addition, microRNAs have been
 shown to have different expression levels in certain diseased versus normal
 tissues. As a result, these differences potentially provide for a novel
 diagnostic strategy for many diseases. MicroRNAs are thought to play a key
 role in the differentiation of cells into specific cell types performing
 various functions in the body.
     About Rosetta Genomics
     Rosetta Genomics (NASDAQ:   ROSG) is a leader in the development of
 microRNA-based diagnostics and therapeutics. Founded in 2000, the company's
 integrative research platform combining bioinformatics and state-of-the-art
 laboratory processes has led to the discovery of hundreds of biologically
 validated novel human microRNAs. Building on its strong IP position and
 strategic alliances with leading biotechnology companies, Rosetta Genomics
 is working to develop a full range of diagnostic and therapeutic products
 based on microRNAs. The company's primary focus is in the development of
 microRNA-based products to diagnose and treat different forms of cancer and
 infectious diseases.
     Forward-Looking Statement Disclaimer
     Various statements in this release concerning Rosetta's future
 expectations, plans and prospects, including without limitation, statements
 relating to the role of miRNAs in human physiology and disease, the
 potential of microRNAs in the diagnosis and treatment of disease, and the
 possible identification of a novel diagnostics approach for targeting
 miRNAs, constitute forward-looking statements for the purposes of the safe
 harbor provisions under The Private Securities Litigation Reform Act of
 1995. Actual results may differ materially from those indicated by these
 forward-looking statements as a result of various important factors,
 including risks related to: Rosetta's approach to discover and develop
 novel diagnostics products, which is unproven and may never lead to
 marketable products; Rosetta's ability to fund and the results of further
 pre-clinical and clinical trials; obtaining, maintaining and protecting
 intellectual property utilized by Rosetta's products; Rosetta's ability to
 enforce its patents against infringers and to defend its patent portfolio
 against challenges from third parties; Rosetta's ability to obtain
 additional funding to support its business activities; Rosetta's dependence
 on third parties for development, manufacture, marketing, sales, and
 distribution of products; the successful development of Rosetta's product
 candidates, all of which are in early stages of development; obtaining
 regulatory approval for products; competition from others using technology
 similar to Rosetta's and others developing products for similar uses;
 Rosetta's dependence on collaborators; and Rosetta's short operating
 history; as well as those risks more fully discussed in the "Risk Factors"
 section of Rosetta's most recent Registration Statement on Form F-1 on file
 with the Securities and Exchange Commission. In addition, any
 forward-looking statements represent Rosetta's views only as of today and
 should not be relied upon as representing its views as of any subsequent
 date. Rosetta does not assume any obligation to update any forward-looking
 statements unless required by law.
     Contact: Media & Investors
     Ron Kamienchick
     T: +972-8-948-4785

SOURCE Rosetta Genomics Ltd